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Background/aim: There is limited information about peripheral blood eosinophilia (PBE) and airway obstruction in sarcoidosis. Since
pulmonary sarcoidosis affects the airways, it is often confused with asthma. The aims of the study are to investigate airway obstruction
and PBE in sarcoidosis patients and to examine the similarity of clinical presentation with asthma.
Materials and methods: The patients matching the ATS/ERS/WASOG diagnosis criteria and were between 18 and 80 years of age were
included consecutively between 2018 and 2020. Other diseases causing granulomas were excluded.
Results: A total of 84 patients were included of which 26 (31%) had a PBE level of ≥300 µL with no significant difference seen between
sarcoidosis stage and PBE (p > 0.05). A significant (p < 0.05) decrease was only seen in FEV1 as the stage of sarcoidosis progressed.
Respectively 31 (36.9%), 12 (14.3%) and 4 (4.8%) patients had an obstructive, restrictive and mixed respiratory function disorder.
Twenty-four (28.6%) subjects with sarcoidosis had history of asthma. Spring fever, eczema, and skin/nose allergy were noticed in 17
(20.2%) of the patients.
Conclusion: Mild PBE may be seen in sarcoidosis. Patients applying with PBE, airway obstruction, bronchial hyperreactivity along
with spring fever, eczema, skin/nose allergy, wheezing, chest tightness, shortness of breath and cough may be also evaluated in terms
of sarcoidosis.
Key words: Airway obstruction, asthma, eosinophilia, sarcoidosis

1. Introduction
Sarcoidosis is a systemic disease which causes an immunerelated noncaseous granuloma formation in the involved
organ [1]. This disease can be seen worldwide and affects all
ages and races [2]. Genetic, infectious and environmental
factors along with occupational exposures are thought to
be etiologic factors of sarcoidosis [3,4].
Although most patients with sarcoidosis have normal
pulmonary function test (PFT), restrictive, obstructive
or mixed disorder can also be observed [5]. Airway
involvement is common in sarcoidosis and granulomatous
inflammation can be seen in approximately 60% of
endobrochial biopsies [6]. Endobronchial granulomas
may cause narrowing, distortion or complete obstruction
in the airways [7,8]. Sarcoid granulomas can also progress
to fibrosis and cause severe contraction and distortion in
the airways [9,10]. Temporary airway obstruction can be
seen in up to 58% of sarcoidosis patients due to bronchial
hyperreactivity and bronchospasm [11–13]. Restrictive
disorders usually result from advanced parenchymal

fibrosis due to interstitial pneumonia which is
accompanied by sarcoid granulomas and/or sarcoidosis.
Since sarcoidosis affects lung structure, it is generally
characterized as a restrictive lung disease and characterized
by low lung compliance [14]. Diffusing capacity of carbon
monoxide (DLCO) is the most common PFT disorder
in sarcoidosis and the most sensitive test for functional
alveolar surface loss; a decrease in DLCO is thought to
be due to the presence of parenchymal involvement and/
or pulmonary hypertension. Hemoglobin concentration
also plays an important role in DLCO decrease. Anemia
and hematological disorders are common comorbidities
in sarcoidosis which are seen because of infiltration of
the bone marrow with noncaseating granulomas and
decreased iron storage [15]. DLCO decline is a sign of gas
exchange disorder and a decrease in alveolar membrane
diffusion capacity. DLCO drop and desaturation
during exercise is the strongest functional parameter to
demonstrate the severity and progression of sarcoidosis
[16].
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Eosinophilia is defined as an increase in the number of
eosinophils above the normal values observed

in healthy
individuals [17]. No relation was observed between sex and
ethnic factors in terms of eosinophil count. Eosinophilia
causes are many and in general they are divided into
three main categories: primary, secondary (reactive)
and idiopathic [18]. In sarcoidosis patients secondary
eosinophilia may be observed and according to the Guide
of the British Society of Hematology, it has been explained
that mild peripheral blood eosinophilia (PBE) can be seen
in sarcoidosis. The frequency of mild PBE in sarcoidosis is
very variable and may reach up to 25% [19].
This study aimed at evaluating airway obstruction
and PBE in sarcoiosis patients. In addition, it also aimed
at evaluating allergic signs/symptoms and the similarities
between the clinical presentations of sarcoidosis and
asthma in order to help with the differential diagnosis.
2. Materials and methods
The study sample consisted of 84 pulmonary sarcoidosis
patients diagnosed at Erciyes University Medical Faculty.
Sarcoidosis patients were recruited consecutively between
01.02.2018–01.02.2020. Prior to the study, approval was
obtained from the Ethics Committee of Erciyes University
Faculty of Medicine (Ethics Committee approval number:
2018/104) and the patients gave their written informed
consent.
2.1. Patient selection
The patients were included in the study according to
ATS/ERS/WASOG diagnostic criteria for sarcoidosis
and were between 18 and 80 years of age. Those patients
were clinically, radiologically and histopathologically
(noncaseating granuloma on biopsy specimen) compatible
with sarcoidosis. Other diseases causing granulomas such
as typical/atypical tuberculosis, nocardia, actinomycosis,
pneumocystis jirovecii infection, granulomatosis with
polyangiitis, eosinophilic granulomatosis with polyangiitis
and collagen tissue diseases were excluded. Diseases other
than asthma causing peripheral blood eosinophilia (e.g.,
parasitic infections) were also excluded.
2.2. Staging sarcoidosis patients
Stages of sarcoidosis were determined according to the
Siltzbach classification. Stage 0 was determined as normal
chest X-ray, stage 1 bilateral lymphadenopathy, stage
2 bilateral lymphadenopathy with parenchymal lung
disease, stage 3 only parenchymal lung disease and stage 4
pulmonary fibrosis [20].
2.3. Hemogram
The complete blood count (CBC) was performed as a
routine test for all sarcoidosis patients applying to the
outpatient clinic. The blood samples were drawn from the
venous system of the forearm, collected into potasyum
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ethylene diamine tetra-acetate vacutainer tube and then
sent to the Erciyes University biochemistry laboratory.
Hemoglobin and eosinophil levels were recorded before
initiation of corticosteroid treatment in patients with
treatment indication. In this study, the absolute value of
eosinophils 300 µL and above was accepted as PBE. The cut
off value of 300 µL has been used to evaluate exacerbations
and treatment indications in different disease groups
[21,22].
2.4. Pulmonary function tests/diffusing capacity (DLCO)
Pulmonary function tests were performed with the Viasys
Vmax 20c spirometer device in Erciyes University Medical
Faculty Chest Diseases outpatient clinic. Tests were
performed with patients in an upright sitting position.
After performing at least three acceptable maneuvers for
the PFT, the best test was recorded. The patients were
given 400 mcg salbutamol by inhalation, and after 15
min, a respiratory function test was performed again to
evaluate reversibility. Forced expiratory volume in the first
second (FEV1) was evaluated before and after salbutamol
inhalation and a difference of ≥200 milliliters and ≥12%
in FEV1 was accepted as positive in terms of reversibility.
FEV1/FVC ≤ 75% was accepted as obstructive, FEV1/
FVC ≥ 75% and FVC < 80% were accepted as restrictive
and FEV1/FVC ≤ 75% with FVC < 80% were accepted as
mixed airway disorders.
DLCO value was measured using the Vmax Encore
device and using carbon monoxide to evaluate alveolocapillary membrane diffusion capacity corrected for
the hemoglobin value of the patients. According to the
measured DLCO (mL/mmHg/min) values; patients were
analyzed into 5 groups as increased (>120%), normal
(80%–120%), slight decrease (60%–79%), moderate
decrease (40%–59%) and severe decrease (<40%) in
diffusion capacity.
2.5. Allergy and asthma symptom survey
This survey was performed by a physician upon
examination to evaluate airway obstruction, atopy,
smoking, family history, self-reported asthma and
asthma-like symptoms in patients with sarcoidosis [23].
This questionnaire is based on that used in the first New
Zealand study [24]. It was then modified slightly from
the one used in the European Community Respiratory
Health Survey (ECRHS) [25]. In this study, the modified
version of ECRHS was used. Before applying the survey,
it was translated to the Turkish language and validated
by some of the chest diseases specialists [26]. To ensure
the reliability of the survey we performed it twice on the
same patients 2 months apart and we got approximately
the same results in both. It was depended on the history of
physician diagnosed self-reported asthma for the diagnosis
and on the survey questions to record the symptoms of the
patients.
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2.6. Statistics
The SPSS software version 22.0 (SSPS Inc., Chicago, Illinois,
USA) was used for statistical analysis. In order to check
whether the data are parametric or not, the distribution
of continuous variables was tested with One-sample
Kolmogorov–Smirnov and the homogenity of variances
was tested with Levene test. Categorical variables were
reported as frequency and group percentages. Categorical
variables were analyzed with the chi-square test. In
comparison of more than two groups one-way ANOVA,
Scheffe test was used. All p values less than 0.05 were
considered significant.
3. Results
Of the 84 patients enrolled in the study 14 (16.7%) were
male and 70 (83.3%) were female with an average age and
body mass index (BMI) of 48.39 kg/m2 ± 12.97 and 30.74
kg/m2 ± 5.26 respectively. As shown in Table 1, the average
PBE was 254.04 µL ± 176.41.
3.1. Sarcoidosis stage and peripheral blood eosinophilia
count
There were no stage 0 patients and 26 (31%), 45 (53.6%),
8 (9.5%) and 5 (6%) patients were categorized as stages
1–4, respectively. Of the 84 patients included in the study,
26 (31%) patients had an absolute PBE ≥ 300 µL on their
complete blood count. Of these patients, 9 (34.6%), 12
(46.1%), 2(7.6%), and 3 (11.5%) patients had stages 1, 2,
3, and 4 sarcoidosis, respectively. There was no significant
difference between the stage of sarcoidosis and PBE (p =
0.286). In this study, bronchoalveolar lavage eosinophilia
was not evaluated. Out of the 26 patients with PBE, 3 were
cigarette smokers while the others had no smoking history.
3.2. Pulmonary function test results
When evaluating the PFT of the patients according to the
stage of the disease, no significant difference was observed
in terms of FEV1/FVC ratio and FVC (in terms of milliliter
and percentage). In contrast, a significant difference was
seen in FEV1 in terms of milliliter (F = 3.842, p = 0.013)
and percentage (F = 2.316, p = 0.041). The effect size (η2)
for FEV1 (percentage) was calculated and it comes out that
the effect was medium-high (η2 = 0.097), whereas the effect
size for FEV1 (milliliter) was high (η2 = 0.126). As the stage
progresses, FEV1 was seen to significantly decrease as
shown in Table 2. As the stage of sarcoidosis progressed
a significant (F = 7.278, p = 0.00) decrease was observed
in DLCO. The calculated effect size for DLCO was the
highest (η2 = 0.214).
When the pattern of respiratory dysfunction was
evaluated normal, obstructive, restrictive and mixed
respiratory patterns were seen in 37 (44%), 31 (36.9%),
12(14.3%), and 4 (%4.8) respectively. From the 31 patients
with an obstructive PFT, 9 patients had a self-reported
asthma history and 2 were smokers. Out of the 84 patients

Table 1. Demographics, laboratory and pulmonary function
tests.
Variable

Average ± SD

Sex M:F (%)

14 (16.7%):70 (83.3%)

Age (years)

48.39 ± 12.97

BMI (kg/m )

30.74 ± 5.26

Hemoglobin (mg/dL)

13.55 ± 1.58

PBE absolute value (per µL)

254.04 ± 176.41

PBE%

3.49 ± 2.35

FEV1/FVC

77.04 ± 7.29

FEV1 (mL)

2403.83 ± 759.21

FEV1%

93.97 ± 18.98

FVC (mL)

3109.52 ± 880.58

FVC%

102.89 ± 18.33

Reversibility (mL)

119.52 ± 106.89

Reversibility%

5.01 ± 4.27

DLCO (mL/mmHg/min)

88.58 ± 19.66

2

SD: Standard deviation, BMI: Body mass index, PBE: Peripheral
blood eosinophilia FEV1: Forced expiratory volume in the 1st
second, FVC: Forced vital capacity, DLCO: Diffusing capacity.

included in the study, 6 (7.1%) had a reversible obstruction
in PFT, 4 of whom had a self-reported asthma history.
3.3. Prevalence of asthma/allergy symptoms in
sarcoidosis
Twenty-four (28.6%) subjects with sarcoidosis had a selfreported history of physician diagnosed asthma and 6
(7.1%) reported an asthma attack in the last 12 months with
13 (15.5%) reporting current use of asthma medication
(none of which was using oral corticosteroid) as shown
in Table 3. Female patients with sarcoidosis were more
likely to have a history of asthma or ever use an asthma
medication than men although it was not statistically
significant (p = 0.385 and 0.622, respectively). Wheezing,
nocturnal symptoms and allergy were also seen more
frequently in women but were not statistically significant
(p = 0.484, 0.378, and 0.424, respectively). Out of the
24 self-reported asthma patients 6 had PBE and asthma
diagnosis did not differ between the stages of sarcoidosis.
4. Discussion
Eosinophilia is described as an elevated level of eosinophils
over healthy subjects. Their production takes place in the
bone marrow and is tightly controlled by transcription
factors and cytokines primarily Interleukin IL-5, IL-3
and granulocyte-macrophage colony-stimulating factor.
These cytokines are the principle drivers of reactive
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Table 2. PBE, pulmonary function tests and diffusing capacity results according to stage of disease.
Stage 1
(n = 26)

Stage 2
(n = 45)

Stage 3
(n = 8)

Stage 4
(n = 5)

PBE

Mean
± SD

280.76

232.66

215.00

370.00

± 216.20

± 151.63

± 117.22

± 216.79

FEV1/ FVC

Mean
± SD

79.1154

75.0667

81.2500

77.4000

± 5.92

± 7.67

± 3.88

± 10.13

FEV1 (mL/sn)

Mean
± SD

2778.15

2270.44

2273.75

1866.00

± 878.70

± 619.36

± 882.20

± 216.17

Mean
± SD

101.80

90.55

92.12

87.00

± 12.65

± 18.88

± 30.44

± 18.34

FVC (mL)

Mean
± SD

1860.00

1540.00

1890.00

1720.00

± 6160.00

± 5450.00

± 4400.00

± 2960.00

FVC (%)

Mean
± SD

108.38

102.00

94.50

98.80

± 13.83

± 17.73

± 28.13

± 22.92

DLCO (%)

Mean
± SD

96.6538

87.9556

85.8750

56.6000

± 16.62

± 16.77

± 28.07

± 10.16

FEV1 (%)

p value*
0.286
0.272
0.013
0.041
0.147
0.182
0.00

PBE: Peripheral blood eosinophilia, SD: Standard deviation, FEV1: Forced expiratory volume in the 1st second, FVC:
Forced vital capacity, DLCO: Diffusing capacity, *One-way ANOVA.

(secondary) eosinophilia which is seen in sarcoidosis
and many other lung diseases [18]. In this study, a total
of 26 (31%) sarcoidosis patients had eosinophilia . The
frequency of mild PBE in sarcoidosis is very variable and
reaches up to 25% [19]. In the study of Renston et al. on
sarcoidosis patients, the PBE frequency was found to
be 41% in sarcoidosis when the threshold value was 4%
[27]. Another study by Renston et al. investigating 178
sarcoidosis patients and using the eosinophilia threshold
value (>4%) found the frequency of eosinophilia to be
35.4%. In their study they explained that the presence
of PBE is not only associated with the accompanying
allergic disease (e.g., asthma, allergic rhinitis) and that
eosinophilia can be directly associated with sarcoidosis
[28]. In our study 26 (31%) patients had PBE, of these
patients 6 had history of asthma. In addition, there was
no significant difference between the sarcoidosis stage
and the mean PBE. In the study by Renston et al., no
significant difference was found between sarcoidosis
stages showing similarity to this study. When these data
were combined, as the sarcoidosis stage increased, there
was no change in the number of eosinophils [27]. In the
future, prospective studies may be needed in order to
define if there is a relation between PBE and exacerbation/
mortality in sarcoidosis patients.
As for the respiratory patterns 31 (36.9%) patients
had obstructive, 12 (14.3%) restrictive and 4 (4.8%)
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mixed airway disorders. Reversibility was observed in 6
(7.1%) patients, four of whom were previously diagnosed
with asthma. Although mostly normal PFT is seen in
sarcoidosis, restrictive, obstructive or mixed disorder can
also be observed. In a study done by Danila et al. only a
minority of the patients had a reduction in lung volume
and airflow obstruction [5]. As for this study, 36.9% of
airflow obstruction were observed in sarcoidosis.
While normal respiratory function test is expected in
most of the sarcoidosis patients, 44.04% normal PFT was
observed in our study. The lower than expected rate was
thought to be due to the absence of stage 0 patients which
may be due to patients being asyptomatic at that stage and
not applying to the hospital. Also another explanation would
be related to the fact that this group of patients may be
overlooked/underdiagnosed because of normal chest X-ray.
Since sarcoidosis primarily affects the lung structure,
it is generally known as a restrictive lung disease. The
restrictive breathing pattern is thought to be due to
advanced fibrosis secondary to parenchymal sarcoid
granuloma and/or concomitant interstitial pneumonia
[14]. In a study, the frequency of restrictive and mixed
respiratory dysfunction was found to be 14.6% in newly
diagnosed sarcoidosis patients, while 9.7% obstructive
breathing disorder was observed [29]. In another study,
the frequency of restrictive airway disorder was found
to be 20% [30]. The difference in the obstructive PFT
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Table 3. Asthma/allergy survey.
Total
patients

Male
(n = 14)

Female
(n = 70)

N

%

N (%)

N (%)

Have you ever been diagnosed by your doctor as having asthma?

24

28.6

3 (21.4)

21 (30)

>0.05

If yes—have you had an attack of asthma in the last 12 months?

6

7.1

2 (14.2)

4 (5.7)

>0.05

Have you ever taken medicine (including inhalers, aerosols or tablets) for asthma?

18

21.4

3 (21.4)

15 (21.4)

>0.05

If yes—are you currently taking any medicine (including inhalers, aerosols or tablets)
13
for asthma?

15.5

3 (21.4)

10 (14.2)

>0.05

Have you had wheezing or whistling in your chest at any time in the last 12 months?

21

25.0

4 (28.5)

17 (24.2)

>0.05

If yes—have you been at all breathless when the wheezing noise was present?

15

17.9

2 (14.4)

13 (18.5)

>0.05

Have you had this whistling or wheezing when you did not have a cold?

10

11.9

1 (7.1)

9 (12.8)

>0.05

Have you woken up with a feeling of tightness in your chest at anytime in the last 12
months?

19

22.6

3 (21.4)

16 (22.8)

>0.05

Have you been woken by an attack of shortness of breath at any time in the last 12
months?

18

21.4

2 (14.4)

16 (22.8)

>0.05

Have you been woken by an attack of coughing at any time in the last 12 months?

17

20.2

4 (28.5)

13 (18.5)

>0.05

Do you have allergies such as hay fever, eczema, skin or nose allergy?

17

20.2

2 (14.2)

15 (21.4)

>0.05

Did/does your mother have asthma?

9

10.7

0 (0)

9 (12.8)

>0.05

Did/does your mother have any allergies such as hay fever, eczema, skin or nose
allergy?

1

1.2

0 (0)

1 (1.4)

>0.05

Did/does your father have asthma?

Survey questions

p
value*

8

9.5

1 (7.1)

7 (10)

>0.05

Did/does your father have any allergies such as hay fever, eczema, skin or nose allergy? 1

1.2

0 (0)

1 (1.4)

>0.05

Do any of your brothers and sisters have asthma?

7

8.3

0 (0)

7 (10)

>0.05

Do any of your brothers and sisters have any allergies such as hay fever, eczema, skin
or nose allergy?

2

2.4

0 (0)

2 (2.8)

>0.05

Have you ever smoked for as long as a year?

14

16.7

3 (21.4)

11 (15.7)

>0.05

Do you smoke now as of one month ago?

4

4.8

1 (7.1)

3 (4.2)

>0.05

*Chi-square test.

ratio from other studies and this one may be due to the
abscence of stage 0 patients, the nonhomogen female to
male ratio and the extent of lung paranchyma and airway
involvement.
One study was performed on 80 stages 1–3 sarcoidosis
patients, and as the stage progressed, a significant decrease
was observed in FEV1% and FVC%, but no significant
decrease in FEV1/FVC ratio was noticed [19]. In another
study, the evaluation of PFT values of 130 stages 1–4
sarcoidosis patients showed a significant decrease in
FEV1/FVC, FEV1% and FVC%, respectively, as the stage
progressed [31]. In this study, only FEV1 (milliliters
and percentage) decreased significantly as the stage
progressed. This significant decrease was thought to be
due to endobronchial sarcoidosis granulomas causing
endobronchial fibrosis and narrowing in the airways [30].
As for the absence of significant decrease in FEV1/FVC

and FVC, it is thought to be due to the low number of
stages 3 and 4 sarcoidosis patients.
In a study done upon 228 sarcoidosis patients no
reversible PFT was observed [32]. However, a review of
sarcoidosis showed that approximately 20% of patients
have airway hyperreactivity [29]. It is recommended to use
inhaled corticosteroids (ICS), especially in cough associated
with sarcoidosis. It is thought that ICS has a suppressive
effect on both airway hyperreactivity and granuloma in the
airway [31]. About 7.1% of our patients had a reversible PFT
and these patients may benifit from ICS but further studies
may be needed. Out of the 14 patients with smoking history
only 2 had an obstructive airway disorder. At the same time,
9 out of 31 patients with obstructive PFT had a history of
asthma. Considering these results, it was understood that
airway obstruction due to sarcoidosis alone can be observed
in accordance with the literature [5].
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Out of the 84 patients included in the study 6 (7.1%)
had a reversible obstruction in PFT, 4 of whom had a selfreported asthma history.
The average DLCO of the patients included in the study
was found to be 88.58%. Increased diffusioncapacity for
carbon monoxide was observed in 6 patients. All of these
patients had a history of asthma and it was concluded that
this increase may be due to asthma. While most of the
patients (58.3%) had normal DLCO values, 29 patients
(34.5%) had low DLCO. Due to parenchymal involvement
and fibrosis alveo-capillary membrane thickening in
sarcoidosis, a decrease in DLCO is expected. DLCO is
known as the most sensitive parameter to detect functional
alveolar surface area loss. In two separate studies, as the
sarcoidosis stage progressed, a significant decrease in DLCO
values of 80 stages 1–3 sarcoidosis patients in the first and
130 stages 1–4 sarcoidosis patients in the second study were
observedwhich is compatible with our findings [30,31].
Considering the results obtained from the survey,
it is understood that obstructive airway disorder and
reversible PFT can be seen in patients with sarcoidosis
without history of asthma and smoking. Wheezing, chest
tightness, shortness of breath and cough can be seen in both
asthma and sarcoidosis. It was also observed that hay fever,
eczema, skin and nose allergy may be seen both in asthma
and sarcoidosis. Therefore, having very similar findings
and symptoms between asthma and sarcoidosis can delay
the diagnosis of sarcoidosis. As a result, we may be able to
say that atopic diseases frequently accompany sarcoidosis.
In such patients who are diagnosed with asthma and did
not respond well to treatment, a lung tomography may be
needed for futher evaluation.
5. Limitations
We had some limitations to our study such as not having a
control group in which PBE could be compared. The stages
of sarcoidosis patients were not homogenous in terms
of patient numbers in each group and the general patient

population was low. To evaluate atopy and allergy in more
detail serum specific IgE and skin prick test could have been
more helpful along with the survey. Although patients were
included consecutively to the study the patient population
was mostly women.
6. Conclusion
Mild PBE may be seen in sarcoidosis patients but it is
independent from the disease stage. Patients applying with
PBE, airway obstruction, bronchial hyperreactivity, hay
fever, eczema, skin/nose allergy, wheezing, chest tightness,
shortness of breath and cough whom are evaluated in
terms of asthma but do not respond to treatment may
need to be evaluated for sarcoidosis. Since the symptoms
are not specific to sarcoidosis, it can sometimes be difficult
to diagnose asthma in a patient who has previously been
diagnosed with sarcoidosis.
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